JP Morgan Maintains Overweight on Privia Health Gr, Lowers Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Lisa Gill has maintained an Overweight rating on Privia Health Group (NASDAQ:PRVA) but has reduced the price target from $43 to $38.
November 17, 2023 | 4:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Privia Health Group's stock may experience short-term price movement due to JP Morgan's price target reduction from $43 to $38, despite maintaining an Overweight rating.
While the reduction in price target could be seen as a negative signal, the maintenance of an Overweight rating suggests that JP Morgan still sees positive fundamentals in PRVA. The mixed signals may lead to neutral short-term price movement as the market digests the news.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100